NCT05403723 2026-02-19
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
University of Maryland, Baltimore
Phase 1 Suspended
University of Maryland, Baltimore
M.D. Anderson Cancer Center
Stanford University
JS InnoPharm, LLC
NextPoint Therapeutics, Inc.
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
GlaxoSmithKline